Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Monte Rosa Therapeutics Inc (GLUE)

Monte Rosa Therapeutics Inc (GLUE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Monte Rosa Therapeutics Inc 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118 USA

www.monterosatx.com Employees: 134 P: 617-949-2643

Sector:

Medical

Description:

Monte Rosa Therapeutics Inc. is a biotechnology company. It involved in developing a portfolio of novel small molecule precision medicines which employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. Monte Rosa Therapeutics Inc. is based in BOSTON.

Key Statistics

Overview:

Market Capitalization, $K 1,270,452
Enterprise Value, $K 1,046,202
Shares Outstanding, K 65,118
Float, K 60,885
% Float 93.50%
Short Interest, K 7,664
Short Float 11.77%
Days to Cover 6.73
Short Volume Ratio 0.72
% of Insider Shareholders 6.50%
% of Institutional Shareholders 79.96%

Financials:

Annual Sales, $ 75,620 K
Annual Net Income, $ -72,700 K
Last Quarter Sales, $ 12,770 K
Last Quarter Net Income, $ -27,080 K
EBIT, $ 8,510 K
EBITDA, $ 16,630 K

Growth:

1-Year Return 228.94%
3-Year Return 204.20%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.33 on 11/06/25
Next Earnings Date 03/19/26 [--]
Earnings Per Share ttm 0.32
EPS Growth vs. Prev Qtr -120.00%
EPS Growth vs. Prev Year -13.79%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

GLUE Ratios

Ratio
Price/Earnings ttm 59.31
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 8.28%
Return-on-Assets % 5.07%
Profit Margin % -96.14%
Debt/Equity 0.00
Price/Sales 8.75
Price/Cash Flow N/A
Price/Book 4.77
Book Value/Share 3.98
Interest Coverage -0.99
60-Month Beta 1.61
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar